This is the same warning that sits on semaglutide and liraglutide
Retatrutide (LY-3437943) is a next-generation triple incretin receptor agonist that simultaneously activates the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R)
Older medications include liraglutide (Saxenda), naltrexone-bupropion (Contrave), phentermine-topiramate (Qsymia), and orlistat (Alli, Xenical)
Relationship dynamics and partner factors also influence sexual function
Several aspects make Retatrutide stand out from other weight loss medications currently available: Preservation of Muscle Mass: One of the key concerns with significant average weight loss is the potential for muscle loss, which can lead to weakness and a slower metabolism
In a study utilizing Ex-4-loaded nanotube-fiber matrices, the scaffolds demonstrated excellent cytocompatibility, supporting cell attachment and proliferation regardless of whether Ex-4 was embedded within the matrix or supplied exogenously through the culture medium
